The major pharmaceutical company Allergan, owned by AbbVie, has issued a recall of two eye ointments under the ... The FDA ...
In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion. The company also raised the combined peak sales guidance of oral CGRP ...
1 AbbVie and REGENXBIO are advancing the development of two separate routes of administration of ABBV-RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery ...
AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...
The company said it is keeping an eye on TNF-like ligand 1A (TL1A) therapies to be used in combination with Skyrizi which it hopes could become the new standard of care. AbbVie also spoke about ...